INmune Bio
INMB
41 hedge funds and large institutions have $30.6M invested in INmune Bio in 2021 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 7 increasing their positions, 5 reducing their positions, and 10 closing their positions.
98% more capital invested
Capital invested by funds: $15.5M → $30.6M (+$15.1M)
80% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 10
40% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 5
24% more funds holding
Funds holding: 33 → 41 (+8)
2.9% more ownership
Funds ownership: 8.75% → 11.65% (+2.9%)
7% more call options, than puts
Call options by funds: $1.04M | Put options by funds: $972K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EI
EAM Investors
Solana Beach,
California
|
+$2.18M |
| 2 |
EGI
EAM Global Investors
Solana Beach,
California
|
+$1.57M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$889K |
| 4 |
Janney Montgomery Scott
Philadelphia,
Pennsylvania
|
+$773K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$755K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
-$1.17M |
| 2 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$536K |
| 3 |
Millennium Management
New York
|
-$499K |
| 4 |
BlackRock
New York
|
-$481K |
| 5 |
HF
HRT Financial
New York
|
-$262K |
INMB Hedge Fund Activity: Q2 2021 in Review
41 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in INmune Bio (INMB) for Q2 2021, worth a combined $30.6M — up 98% from $15.5M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new INMB positions and 10 closed out — a net gain of 8 holders — while 7 added to existing stakes and 5 trimmed.
The largest buyer was EAM Investors, opening a new position worth an estimated $2.18M. The largest seller was Ikarian Capital, cutting an estimated $1.17M.
- 41 institutional investors held INmune Bio (INMB) as of Q2 2021, up from 33 in Q1 2021.
- Funds reported $30.6M of INmune Bio stock for Q2 2021, up 98% quarter-over-quarter.
- 18 funds opened new INmune Bio positions in Q2 2021 and 10 closed out, a net change of +8 holders.
- The largest INmune Bio buyer in Q2 2021 was EAM Investors, an estimated $2.18M added.
- The largest INmune Bio seller in Q2 2021 was Ikarian Capital, an estimated $1.17M sold.
Based on aggregated 13F filings for Q2 2021.